Advertisement

Waltham biotech Repligen Corp. (Nasdaq: RGEN) has received U.S. Food and Drug Administration Fast Track designation for RG3039, a potential treatment for Spinal Muscular Atrophy (SMA), according to a press release issued by the company.

That designation is designed to expedite the review of drugs that treat serious diseases and fill an unmet medical need.

SOURCE

Advertisement
Advertisement